269 results on '"Waters, David D."'
Search Results
2. Usefulness of Angina to Guide Revascularization Decisions
3. Notes From Cardiology Clinic: You Can't Ride With the Cops, But Cheer for the Robbers
4. Notes From Cardiology Clinic: Cinderella’s Electronic Medical Record
5. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
6. Changing the Face of Cardiovascular Trial Participation: Moving Beyond Middle-Aged White Guys
7. Notes From Cardiology Clinic: Mitral Stenosis and Racial Discordance
8. Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT
9. The association between lipid levels and leukocyte count: A cross-sectional and longitudinal analysis of three large cohorts
10. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib
11. Notes From Cardiology Clinic: Trouble for Tongans
12. Notes From Cardiology Clinic: The Heartbreaking Risk Factor We Overlook
13. Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?
14. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
15. Notes From Cardiology Clinic: Health Care Heroine, Unpaid and Unappreciated
16. Inflammation in Cardiovascular Disease: From Basic Concepts to Clinical Application
17. Notes From Cardiology Clinic: Brittle Bones and Blue Sclerae
18. Notes From the Cardiology Clinic: Facing Down the Dragons of Health Anxiety
19. Erratum to “Notes From Cardiology Clinic: The Patients We Dislike”
20. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
21. When Diastole Lets You Down: Clinical Relevance of a Widened Pulse Pressure
22. Notes From Cardiology Clinic: The Patients We Dislike
23. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
24. WITHDRAWN: Notes From Cardiology Clinic: The Patients We Dislike
25. Treatment of Cardiovascular Manifestations of HIV
26. Contributors
27. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
28. Notes From Cardiology Clinic: Woman, Lost During Follow-up
29. Pathophysiology of Acute Coronary Syndromes
30. Notes From Cardiology Clinic: When Our Responsibilities Extend Beyond the Patient
31. Improving Statin Noncompliance: If You Build It, Will They Come?
32. HIV infection and coronary heart disease: mechanisms and management
33. Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials
34. Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now
35. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)
36. Lipid Abnormalities in Persons Living With HIV Infection
37. Introduction to Cardiovascular Issues in HIV
38. Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus
39. Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor
40. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial
41. Variations in time to benefit among clinical trials of cholesterol-lowering drugs
42. Lipids, inflammation, and chronic kidney disease: a SHARP perspective
43. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events
44. Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin
45. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
46. Taking Hockey to Heart: Potential Coronary Risks of Watching Exciting Games
47. Are Cholesterol Treatment Targets a Deterrent to Optimal Lipid-Lowering Therapy?
48. Heart failure in persons living with HIV infection
49. The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence
50. PCSK9 Inhibition to Reduce Cardiovascular Risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.